RecruitingNot ApplicableNCT07002723

Effects of Esketamine Combined With Dexmedetomidine on Postoperative Sleep Quality

Effects of Esketamine Combined With Dexmedetomidine on Postoperative Sleep Quality in Elderly Patients Undergoing Hip Surgery:A Superiority Randomized Controlled Trail


Sponsor

Peking University Shenzhen Hospital

Enrollment

96 participants

Start Date

Jun 20, 2025

Study Type

INTERVENTIONAL

Conditions

Summary

1. Eligible patients are randomly divided into experimental and control groups; 2. The experimental group is given esketamine combined with dexmedetomidine,while the control group is given normal saline; 3. The patients' sleep, pain, and cognition are followed up after surgery.


Eligibility

Min Age: 65 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a drug called Esketamine combined with dexmedetomidine and a drug called Normal saline for people with hip fractures. The study is currently recruiting participants at 1 location.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGEsketamine combined with dexmedetomidine

After successful neuraxial anesthesia, 0.125mg/kg esketamine and 0.3ug/kg dexmedetomidine are diluted into 30ml of normal saline and continuously pumped for 20 minutes, then connected to a micropump: 15ug/kg/h esketamine 0.02ug/kg/h dexmedetomidine to 96ml saline, continuous amount: 2ml/h, continuous pumping for 48h.

DRUGNormal saline

After successful neuraxial anesthesia, 30ml of normal saline was continuously pumped for 20 minutes, followed by a micropump: 96ml of saline, continuous amount: 2ml/h for 48h.


Locations(1)

Peking University Shenzhen Hospital

Shenzhen, Guangdong, China

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT07002723


Related Trials